Results 71 to 80 of about 4,640 (210)

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series

eJHaem
This report describes the characteristics and outcomes of 18 heavily pretreated patients with multiple myeloma (MM) who were subsequently treated with selinexor.
Nini Aung, Margaret Bowers, Gillian Brearton, Andrew Charlton, Joanne Craig, Jonathan Cullis, Ray Dang, David Donaldson, Mary Drake, Rachel Hall, Elizabeth Parkins, Jane Tighe, Ceri Bygrave, Oonagh Sheehy   +13 more
doaj   +1 more source

Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 17, September 2026.
ABSTRACT Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment‐naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta‐analysis was intended to evaluate their efficacy, addressing critical gaps
Fangfei Xu, Xiuping Zou, Yulin Yang, Kuangguo Zhou, Wei Huang   +4 more
wiley   +1 more source

Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro

BMC Pharmacology and Toxicology
Selinexor (SLX), a selective inhibitor of nuclear export (SINE), has been shown to interfere with nuclear export mechanisms and to exert antitumor effects in a variety of cancer cell types. It is known to regulate multiple fundamental cellular processes,
M. Öztatlıcı, Parmila Rahmat Zada, R. Çolaksel, B. Halıcıoğlu, Hülya Öztatlıcı   +4 more
semanticscholar   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents‐Based Induction Therapy

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Extramedullary disease (EMD) in newly diagnosed multiple myeloma (NDMM) is aggressive and associated with worse survival. This study aimed to comprehensively evaluate the clinical outcomes and factors affecting prognosis in NDMM patients with EMD receiving novel agents‐based induction therapy.
Xiaoxi Xu, Yiru Wang, Wenhuan Zhang, Xin Liu, Luqun Wang, Jun Peng, Ming Hou, Hai Zhou   +7 more
wiley   +1 more source

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

Therapeutic Advances in Medical Oncology
Background: Selinexor (SEL) is an oral inhibitor of nuclear export protein Exportin 1 (XPO1) previously shown to upregulate programmed cell death protein 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression.
J. Choo, Santhiay Nathan Jeraj, R. Sundar, W. Yong, Matilda Lee, Yiqing Huang, Y. Asokumaran, G. Chan, N. Ngoi, A. Wong, Ross A. Soo, C. Chee, J. Lim, Bo-On C. Goh, Soo-Chin Lee, D. Tan   +15 more
semanticscholar   +1 more source

Drug Resistance in Multiple Myeloma: Tumor‐Intrinsic Mechanisms and the Bone Marrow Microenvironment

Cell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder, and despite substantial improvements in prognosis achieved through chemotherapy, immunotherapy, and autologous stem cell transplantation, most patients ultimately develop relapsed or refractory disease. Drug resistance (DR) is increasingly recognized as a dynamically evolving ecosystem
Yixuan Chen, Wenming Huang, Mingxuan Tang, Xiaotao Wang   +3 more
wiley   +1 more source

The synergy of TPL and selinexor in MLL-R acute myeloid leukemia via Rap1/Raf/MEK pathway-mediated MYC downregulation

Translational Oncology
Highlights • Low doses of triptolide (LD TPL) and the XPO1 inhibitor selinexor exert synergistic therapeutic effects on preclinical MLL-r AML models.• Promotion of the mitochondrial apoptotic pathway were closely involved in the therapeutic synergy of LD
Manman Deng, P. Huang, Li-Juan Wang, Yuelong Jiang, Zhenling Guo, Hongpeng Duan, Jie Zha, Haijun Zhao, Guo-Wei Li, Bing Xu   +9 more
semanticscholar   +1 more source

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2‐Year Follow‐Up From MajesTEC‐1 China Cohort

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction With an additional year of follow‐up compared with the previous report, this study presents the 27.2‐month efficacy and safety outcomes of the MajesTEC‐1 China cohort. Methods A total of 26 participants with triple‑class exposed relapsed/refractory multiple myeloma (TCE‐RRMM) received subcutaneous teclistamab 1.5 mg/kg weekly ...
Zhen Cai, Zhongjun Xia, Aili He, Yujun Dong, Yafei Wang, Aijun Liao, Yang Song, Hongye Chen, Athena Zuppa, Katherine Chastain, Latisha Watkins, Xinchao Luo, Lin Huang, Hongmei Xu, Longen Zhou, Wannan Chen, Angeline Zhu, Xiaohong Wang, Weijun Fu, Ting Niu, Juan Du   +20 more
wiley   +1 more source

Parallel Phase II Clinical Trials of Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma

JTO Clinical and Research Reports
Introduction Thymic epithelial tumors (TETs) are rare and include thymomas (T) and thymic carcinomas (TC). Effective treatment options are needed for patients with progressive disease after platinum-based chemotherapy.
Chul Kim, Vanya Aggarwal, G. Daugaard, Tian-Zhi Tang, J. Ahn, B. Besse, N. Girard, G. Giaccone, Peter M. Petersen   +8 more
semanticscholar   +1 more source